World and News Statement.
Related StoriesDrug compounds focus on multiple pathways connected with myotonic dystrophy type 1Specific gut bacterias can improve malignancy immunotherapy, show studiesGenetic reduced amount of AMPK enzyme can prevent or delay hearing lossThe scope of the collaborations between experts and clinicians from these leading educational medical organizations and BioImagene consist of co-development of fresh Companion Algorithms for Companion Diagnostics for breasts, prostate, lung, gastro-intestinal and liver tumor, and validation of integrated diagnostic workstations to be utilized by pathologists in scientific practice.This process represents a robust opportunity in immuno-oncology to simultaneously engage immune cells and tumor cells to localize anti-tumor immune activity where it really is needed most. Amgen, which includes pioneered the use of bispecific antibodies, has chosen to gain access to our XmAb bispecific technology for its robustness, lengthy half-existence, and the plug and play ease-of-advancement of our system, stated Bassil Dahiyat, Ph.D., president and ceo of Xencor. This opportunity expands the reach of our technology with a partner that has proven experience in bispecifics and immuno-oncology. Xencor will continue to focus on its internal applications including its immuno-oncology XmAb bispecifics, XmAb14045 in acute myeloid XmAb13676 and leukemia in B-cell malignancies, which are expected to enter clinical advancement in 2016.